Safe, effective COVID-19 vaccine may not arrive until April 2021 or later
Share Now on:
According to news reports, the FDA wanted new, stricter rules for coronavirus vaccines but that the White House blocked this, saying there was no medical reason. The tougher rules regulators wanted very likely would have meant no vaccine approvals before the election.
And there’s a new global analysis suggesting the first approved vaccines might not come until later still, perhaps next spring. Marketplace’s Nova Safo has the latest, and he spoke with “Marketplace Morning Report” host David Brancaccio. The following is an edited transcript of their conversation.
David Brancaccio: Where is this estimate of a vaccine timeline coming from and what does it say specifically?
Nova Safo: It’s coming from a group that takes a more global view of the pandemic and is looking at stringent vaccine approval standards. The Center for Global Development, which is a think tank, did some mathematical modeling and combined that with expert interviews. It came up with a 50% chance of at least one vaccine by April of next year — a vaccine that’s deemed safe and effective. It says there’s an 85% chance of a vaccine by end of 2021.
I spoke this morning with Anthony McDonnell, senior policy analyst at the Center for Global Development, about why it will take that long.
Anthony McDonnell: It takes a very long time to collect data on the 30,000-plus people that you need to run through clinical trial. And if you want to have six months worth of safety data on your vaccine, you need to vaccinate people and wait for six months.
Safo: The New York Times says that the FDA wants a two-month median follow-up time for current trials. That’s reportedly not been approved yet.
Brancaccio: We know that vaccine approval is just the first step — there’s a logistics operation that comes after. How long is manufacturing enough vaccines for everyone projected to take?
Safo: McDonnell told me there is enough vaccine manufacturing capacity globally. But there is a catch.
McDonnell: The slow thing is that you have to redesign factories such that they can make these products and that can take up to a year, 18 months before you get factories ready to start making vaccines at really large scale.
Safo: He says if we get multiple vaccines approved, that could speed up production.
Brancaccio: Is there modeling on how a longer timeline for a vaccine might impact the economy?
Safo: For that we turn to the Organization for Economic Cooperation and Development — it’s assuming that there won’t be widespread deployment of a vaccine until the end of next year, and with that, expects the global economy to grow by 5% and the U.S. economy to grow by 4%. That won’t take us back to the pre-pandemic trajectory we were on, but it’s better than previously forecast.
COVID-19 Economy FAQs
What’s the outlook for vaccine supply?
Chief executives of America’s COVID-19 vaccine makers promised in congressional testimony to deliver the doses promised to the U.S. government by summer. The projections of confidence come after months of supply chain challenges and companies falling short of year-end projections for 2020. What changed? In part, drugmakers that normally compete are now actually helping one another. This has helped solve several supply chain issues, but not all of them.
How has the pandemic changed scientific research?
Over the past year, while some scientists turned their attention to COVID-19 and creating vaccines to fight it, most others had to pause their research — and re-imagine how to do it. Social distancing, limited lab capacity — “It’s less fun, I have to say. Like, for me the big part of the science is discussing the science with other people, getting excited about projects,” said Isabella Rauch, an immunologist at Oregon Health & Science University in Portland. Funding is also a big question for many.
What happened to all of the hazard pay essential workers were getting at the beginning of the pandemic?
Almost a year ago, when the pandemic began, essential workers were hailed as heroes. Back then, many companies gave hazard pay, an extra $2 or so per hour, for coming in to work. That quietly went away for most of them last summer. Without federal action, it’s mostly been up to local governments to create programs and mandates. They’ve helped compensate front-line workers, but they haven’t been perfect. “The solutions are small. They’re piecemeal,” said Molly Kinder at the Brookings Institution’s Metropolitan Policy Program. “You’re seeing these innovative pop-ups because we have failed overall to do something systematically.”
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?